Key result
Single-dose rFVIIa (90 microg/kg) successfully managed haemorrhage in 2 of 2 thrombocytopenic patients (100%) and accelerated thrombin generation.
Case Report (n=2)
Answers are grounded in this paper and cite their sources.
We report the ex vivo effect of recombinant activated factor VII (rFVIIa) on prothrombin activation after whole blood clotting. Two patients with severe thrombocytopenia and life-threatening haemorrhage were successfully managed using a single dose of rFVIIa (90 microg/kg). Western blotting using antiprothrombin antibody showed that rFVIIa did not induce thrombin generation in citrated platelet-poor plasma. Patient sera showed significantly impaired prothrombin activation before and after rFVIIa administration. rFVIIa administration shortened the prothrombin time, activated partial thromboplastin time and Ivy bleeding time, and normalized the clot retraction. These data indicate that rFVIIa accelerated thrombin generation without significant increase of generated thrombin.
No takes yet. Share an insight, caveat, or question.
Gerotziafas et al. (2002) conducted a case report in Severe thrombocytopenia and life-threatening haemorrhage (n=2). Recombinant activated factor VII (rFVIIa) vs. Baseline (pre-administration) was evaluated on Management of haemorrhage and ex vivo prothrombin activation after whole blood clotting. Single-dose rFVIIa (90 microg/kg) successfully managed haemorrhage in 2 of 2 thrombocytopenic patients (100%) and accelerated thrombin generation.
Synapse has enriched 10 related papers. Consider them for comparative context: